BioStacks

Supplement

Natural Astaxanthin

Evidence

Moderate

Reviewed May 2026

Evidence: 3 of 5 (Moderate)

9 studies cited · 2 meta-analyses

What the evidence says

Astaxanthin is a xanthophyll carotenoid produced by the microalga Haematococcus pluvialis. Unlike beta-carotene, it has no pro-oxidant activity at any dose. Crosses the blood-retina barrier, making it uniquely effective for eye health.

Several clinical trials on eye health, cardiovascular markers, and skin protection

Top Natural Astaxanthin supplements for…

Supports

SkinModerate
VisionLimited
HeartLimited
Show all 5 areas
LongevityLimited
MusclePreliminary

Top Natural Astaxanthin supplements

3/5

Moderate

9

RCTs reviewed

3

Null results

Genuinely potent antioxidant carotenoid with modest clinical signals for skin elasticity/moisture and screen-related visual fatigue, plus a small lipid (triglyceride/HDL) effect. Most human trials are small and manufacturer-funded. Not a proven ergogenic — endurance and muscle-injury trials are largely null.

Much of the astaxanthin human literature is funded by the companies that sell it (AstaReal/Fuji, BGG, Cyanotech/BioAstin). Trials are small and mostly in healthy Japanese women. Strong antioxidant biomarkers do not equal proven clinical outcomes.

Research dossier

Clinical research on Natural Astaxanthin

9 trials reviewed across 5 indications.

Strongest evidence

Skin elasticity, moisture and UV protection

Moderate

Mechanism

Astaxanthin deposits in skin and quenches singlet oxygen and lipid-peroxidation chains generated by UV exposure. In vitro it suppresses UVB-induced inflammatory cytokines in keratinocytes and matrix-metalloproteinase-1 (collagen-degrading) secretion by fibroblasts — the plausible route to preserved elasticity and dermal collagen.

The pooled meta-analysis (8 RCTs) shows significant improvements in skin moisture and elasticity but NOT in wrinkle depth. The seasonal Tominaga 2017 RCT shows astaxanthin prevented UV-driven worsening of moisture and wrinkles rather than reversing existing damage. Real but modest, and the evidence base is small and heavily manufacturer-led.

Best-evidenced as 'prevented seasonal deterioration' in healthy women at 6–12 mg/day. Not a substitute for sunscreen or retinoids. The anti-wrinkle claim specifically is unsupported by pooled data.

Trials cited

  • Zhou — astaxanthin and skin ageing (systematic review + meta-analysis)

    mixed · Meta-analysis

    Zhou et al., 2021, Nutrientsn=293

    Pooled 8 RCTs (162 astaxanthin vs 131 control). Oral astaxanthin significantly improved skin moisture (SMD 0.53, p=0.03) and elasticity (SMD 0.77, p=0.009) but did NOT significantly reduce wrinkle depth (SMD -0.26, p=0.11). The strongest, most-marketed claim — fewer wrinkles — is the one the pooled data does not support.

    Small samples (all <100/study), mostly healthy Japanese women limiting generalizability, and the authors flag that several included studies were conducted or funded by commercial astaxanthin entities with unclear risk of bias.

  • Tominaga — cosmetic benefits of astaxanthin

    positive · Pilot

    Tominaga et al., 2012, Acta Biochimica Polonican=66Industry-funded

    Open-label study reporting improved skin elasticity, reduced wrinkle area/volume, smaller age-spot size, and better moisture after 8 weeks of 6 mg/day, with the largest effect in the combined oral + topical arm. The most-cited 'astaxanthin for skin' trial.

    Open-label, no placebo control, small per-arm samples, authors affiliated with Fuji Chemical/AstaReal. Open-label designs systematically inflate cosmetic self-rated and instrument outcomes.

  • Tominaga — protective effects of astaxanthin on skin deterioration

    positive · RCT

    Tominaga et al., 2017, Journal of Clinical Biochemistry and Nutritionn=65Industry-funded

    Placebo-controlled trial: over a 16-week UV-heavy season, the placebo group's wrinkles and moisture significantly worsened, while both astaxanthin groups stayed stable. Framed as preventing seasonal UV-driven deterioration rather than reversing existing damage.

    Financially sponsored by Fuji Chemical Industries; all authors affiliated with AstaReal. The benefit is 'prevented worsening,' not active improvement — a weaker claim than marketing implies.

Visual fatigue and eye accommodation

Mechanism

Astaxanthin crosses the blood-retinal barrier and accumulates in ocular tissue, where its antioxidant activity is proposed to support ciliary-muscle accommodation and reduce oxidative strain during sustained near-focus screen work.

Small Japanese RCTs at ~5–9 mg/day report improved accommodation and reduced eye-strain symptoms in screen workers, but the better-controlled Sekikawa 2022 trial found the benefit only in adults over 40, with nothing in younger users. Preliminary and almost entirely industry-linked.

Most credible in over-40 heavy screen users with accommodation decline. Unlike lutein/zeaxanthin, astaxanthin has no hard-endpoint evidence for AMD or cataract.

  • Sekikawa — astaxanthin and visual function after screen work

    mixed · RCT

    Sekikawa et al., 2022, Journal of Clinical Biochemistry and Nutritionn=59Industry-funded

    Randomized, double-blind, placebo-controlled. In participants aged ≥40, astaxanthin protected corrected visual acuity after screen work (p<0.05); in those under 40 there was no significant difference. A modest, age-restricted signal for accommodation/eye-fatigue.

    Sponsored by BGG Japan; two authors were BGG employees. Benefit limited to the over-40 subgroup; younger users showed nothing.

Lipids and cardiovascular markers

Mechanism

As a fat-soluble antioxidant incorporated into LDL particles, astaxanthin is proposed to reduce LDL oxidation and improve adiponectin signaling — directionally favorable for lipid handling and vascular function.

One dose-ranging RCT showed lower triglycerides (12–18 mg) and higher HDL (6–12 mg) tracking with adiponectin. But blood-pressure meta-analysis is null, and there is no cardiovascular outcome (event) data. The cardiovascular case rests on small biomarker trials, not hard endpoints.

Lipid signal is in mild-hypertriglyceridemia adults at 6–18 mg/day. Do not treat astaxanthin as cardiovascular-protective — that claim outruns the evidence.

  • Yoshida — astaxanthin, triglycerides and HDL

    positive · RCT

    Yoshida et al., 2010, Atherosclerosisn=61

    Dose-ranging RCT: 12 and 18 mg/day significantly lowered triglycerides; 6 and 12 mg/day significantly raised HDL-cholesterol, tracking with increased adiponectin. LDL and BMI were unchanged. The first controlled human lipid signal for astaxanthin.

    Biomarker (lipid) endpoints only — no cardiovascular event or outcome data. Small per-dose subgroups, mild-hyperlipidemia population, and the effect has not been consistently replicated.

  • Ooi — astaxanthin and blood pressure (meta-analysis)

    Null · Meta-analysis

    Ooi et al., 2021, Journal of Functional Foods

    Pooled RCTs found only a marginal, non-significant reduction in diastolic blood pressure (MD -1.21 mmHg, 95% CI -2.51 to 0.09) and no effect on systolic blood pressure. Despite a plausible vascular-antioxidant mechanism, astaxanthin does not meaningfully lower blood pressure in humans.

    Heterogeneous populations and doses. The directionally favorable DBP trend crossed zero — this is best read as a null result, not a weak positive.

Antioxidant and immune markers

Mechanism

Astaxanthin's extended conjugated polyene chain and terminal ring hydroxyls make it an unusually efficient quencher of singlet oxygen and lipid-radical chains. Notably, it does not flip to a pro-oxidant at high concentration the way some carotenoids can — a genuine structural advantage as an antioxidant.

In young healthy women, astaxanthin lowered a DNA oxidative-damage marker (8-OHdG) and CRP and enhanced several immune-cell measures. The antioxidant biochemistry is real and well-characterized — but reduced biomarkers are not the same as a proven clinical outcome. This distinction is the whole honesty story for astaxanthin.

Biomarker improvements are consistent across small trials. Translating them into disease prevention or longevity is unproven extrapolation.

  • Park — astaxanthin, oxidative stress and immune response

    positive · RCT

    Park et al., 2010, Nutrition & Metabolismn=42

    RCT in young healthy women: astaxanthin lowered a DNA oxidative-damage marker (8-OHdG) by week 4 — maximal at the lower 2 mg dose — and reduced CRP at week 8 (2 mg). It also raised natural-killer-cell activity, lymphoproliferation, and T/B-cell subsets. Did not change lipid peroxidation.

    Biomarker and ex-vivo immune endpoints, not clinical outcomes. Small sample, single population. The non-linear dose response (2 mg outperforming 8 mg on some markers) complicates dose interpretation.

Exercise performance and recovery

Mechanism

The ergogenic hypothesis is that astaxanthin's antioxidant action spares mitochondria and shifts fuel use toward fat oxidation during endurance work. Mechanistically plausible from rodent data; human translation has largely failed.

The two most rigorous human trials are null: 20 mg/day did not improve fat oxidation or time-trial performance in trained cyclists (Res 2013, independent), and 4 mg did not reduce muscle soreness or creatine kinase after eccentric exercise (Bloomer 2005). Some newer small trials report reduced subjective soreness at 12 mg, but performance benefit is not established.

Not a proven ergogenic aid. Trained athletes — the people most likely to buy it — showed no performance benefit in the cleanest trial.

  • Res — astaxanthin does not augment fat use or endurance performance

    Null · RCT

    Res et al., 2013, Medicine & Science in Sports & Exercisen=32

    Despite raising plasma astaxanthin ~10-fold, 20 mg/day for 4 weeks did not change fat-oxidation rates, antioxidant capacity, or time-trial performance in trained cyclists. A clean, independent (non-industry) null that contradicts the ergogenic marketing.

    Well-trained athletes already have high endogenous antioxidant capacity, which may blunt any benefit. Still, it is one of the most rigorous astaxanthin performance trials and it found nothing.

  • Bloomer — astaxanthin and eccentric muscle injury

    Null · RCT

    Bloomer et al., 2005, International Journal of Sport Nutrition and Exercise Metabolismn=20

    After a damaging eccentric leg-press protocol, astaxanthin (with lutein) produced no benefit over placebo on muscle soreness, creatine kinase, or performance recovery at any timepoint through 96 hours.

    Small sample; the supplement combined astaxanthin with lutein, so it does not isolate astaxanthin. Newer trials report reduced subjective soreness at higher (12 mg) doses, but the recovery literature remains inconsistent.

3 forms of Natural Astaxanthin compared
  • AstaReal®, BioAstin®

    Natural astaxanthin (Haematococcus pluvialis)

    Fat-soluble — absorption requires a fat-containing meal

    Best forThe form used in essentially every human trial — skin, eye, lipid, antioxidant

    Microalgae-derived natural astaxanthin is predominantly the trans isomer and exists mostly as mono- and di-esters (esterified with fatty acids). This is the form behind all the human evidence. Branded clinical-grade material (AstaReal/Fuji, Cyanotech BioAstin) dominates the trial literature.

  • Astaxanthin oleoresin

    Fat-soluble; oil matrix aids absorption

    Best forConcentrated natural-astaxanthin extract used in most softgels

    Oleoresin is the oil-soluble extract of Haematococcus biomass, typically standardized (e.g. 5–10% astaxanthin) and delivered in softgels. Label percentage matters — check the actual astaxanthin milligrams, not the oleoresin weight.

  • Synthetic astaxanthin

    Free (non-esterified) form; differing isomer profile from natural

    Best forPredominantly aquaculture/fish-feed pigment — NOT the studied human form

    Petrochemically synthesized astaxanthin is mostly free (unesterified) and contains a different stereoisomer mix than the natural microalgal product. It is used overwhelmingly to color farmed salmon and is not the form behind the human clinical trials. For supplement use, choose natural Haematococcus-derived astaxanthin.

Are you deficient? Symptoms, risk groups, lab tests

Astaxanthin is not an essential nutrient and has no RDA or recognized deficiency state. Dietary intake comes almost entirely from salmon, trout, shrimp, krill, and other seafood that consume astaxanthin-producing algae; typical Western intake is well below supplemental trial doses (4–12 mg/day).

Common symptoms

  • No defined deficiency syndrome — astaxanthin is not classified as essential
  • Low dietary intake simply means no supplemental antioxidant contribution, not a clinical deficiency

Who is at risk

  • Adults eating little seafood

    Wild salmon, trout, shrimp, and krill are the main dietary sources. Low-seafood diets provide essentially no astaxanthin — but this is an absence of a non-essential compound, not a deficiency.

  • Adults on very-low-fat diets or with fat malabsorption

    Astaxanthin is fat-soluble and requires dietary fat for absorption. Bariatric surgery, fat-blockers, and very-low-fat diets all reduce uptake.

Side effects and drug interactions

Side effects

  • Reddish/orange skin tint

    Uncommon · More likely with sustained high intake

    At higher chronic doses the pigment can deposit in skin, producing a harmless reddish or orange tint (analogous to carotenodermia). Cosmetic only and reversible on dose reduction.

  • Mild GI upset

    Uncommon

    Occasional stomach discomfort, looser stools, or increased bowel frequency, usually when taken on an empty stomach. Take with a fat-containing meal to minimize.

  • Mild blood-pressure lowering

    Rare · Higher doses (≥12 mg/day)

    At higher doses astaxanthin may produce a small blood-pressure-lowering effect via vascular antioxidant activity. Trivial for most people, but worth noting alongside antihypertensive medication.

Drug interactions

  • Reduces nutrient status

    orlistatcholestyramineezetimibevery-low-fat diets

    Fat-blockers and bile-acid sequestrants reduce absorption of all fat-soluble carotenoids, including astaxanthin.

    Take astaxanthin with a fat-containing meal, separated from these medications.

  • Additive effect

    antihypertensives

    Astaxanthin's modest blood-pressure-lowering tendency at higher doses could theoretically add to antihypertensive medication, though the blood-pressure meta-analysis was null.

    No routine concern at typical doses; monitor if combining high-dose astaxanthin with blood-pressure medication.

  • Other

    5-alpha-reductase-sensitive conditions (theoretical)

    Astaxanthin has shown 5-alpha-reductase inhibition in vitro (raised in saw-palmetto-style prostate marketing). This is mechanistic/in-vitro only — there is no human evidence of a meaningful hormonal effect.

    Treat as a theoretical, unproven interaction. Do not rely on astaxanthin for any 5-alpha-reductase-mediated effect.

Other critical caveats
  • Most human astaxanthin trials are small (often under 70 people), short, in healthy Japanese women, and funded by the companies that sell it (AstaReal/Fuji, BGG, Cyanotech/BioAstin). Treat single-trial claims with skepticism and weight the independent null trials accordingly.
  • Astaxanthin is a genuinely strong antioxidant on biomarkers (it lowers 8-OHdG, CRP, and lipid peroxidation in vitro and in small trials) — but improved antioxidant biomarkers are not the same as proven clinical outcomes. The biomarker-to-outcome leap is where the marketing overreaches.
  • It is NOT a proven ergogenic. The cleanest endurance trial (Res 2013, 20 mg/day, independent) found no performance or fat-oxidation benefit in trained cyclists, and the classic muscle-recovery trial (Bloomer 2005) was null.
  • Use natural Haematococcus-derived astaxanthin, not synthetic. Synthetic astaxanthin (different isomer/ester profile) is an aquaculture pigment and is not the form studied in humans.
  • Take with a fat-containing meal — astaxanthin is fat-soluble and absorption drops sharply without dietary fat.
Frequently asked
  • What does astaxanthin actually do, with real evidence behind it?
    The best-supported uses are skin moisture and elasticity (pooled RCTs at 6–12 mg/day, though NOT wrinkle reduction) and modest protection against screen-related visual fatigue in over-40 adults. There is a small lipid signal (lower triglycerides, higher HDL) and consistent antioxidant biomarker improvements. The catch: most trials are small and funded by astaxanthin manufacturers, and biomarker changes are not the same as proven clinical outcomes.
  • How much astaxanthin should I take, and when?
    Human trials use 4–12 mg/day — 4 mg for general antioxidant/eye support, 6–12 mg for skin and lipid endpoints. There's no clear advantage above 12 mg for most uses (and the 20 mg endurance trial was null). Always take it with a meal containing fat, since it's fat-soluble.
  • Does astaxanthin improve athletic performance or recovery?
    Not in a proven way. The most rigorous, independent endurance trial (Res 2013, 20 mg/day in trained cyclists) found no effect on performance or fat oxidation, and an early muscle-damage trial (Bloomer 2005) was null. A few newer small trials report reduced subjective soreness at 12 mg, but the recovery literature is inconsistent and performance benefit is not established. Don't buy it as an ergogenic.
  • Is natural astaxanthin different from synthetic?
    Yes, and it matters. Natural astaxanthin from Haematococcus pluvialis microalgae (AstaReal, BioAstin) is the predominantly trans, esterified form used in nearly every human study. Synthetic astaxanthin has a different isomer and ester profile and is used mostly to color farmed salmon — it's not the form behind the human evidence. Choose natural.
  • Is astaxanthin safe? Will it turn my skin orange?
    It's very well tolerated at supplemental doses. At higher chronic intake it can produce a harmless reddish or orange skin tint (like other carotenoids) that reverses when you lower the dose. Mild GI upset is the other occasional complaint — take it with food. There's a theoretical mild blood-pressure-lowering effect at higher doses worth noting if you're on antihypertensives.
  • How does astaxanthin compare to lutein for the eyes?
    They do different jobs. Lutein and zeaxanthin have hard-endpoint trial support (AREDS2) for slowing AMD progression and concentrate in the macula. Astaxanthin's eye evidence is limited to small, mostly industry-funded trials on accommodation and screen-related eye fatigue — useful but preliminary, with no AMD or cataract outcome data. For macular protection, lutein/zeaxanthin is the evidence-backed choice.

References

  1. 01Zhou et al. 2021 — Systematic Review and Meta-Analysis on Astaxanthin and Human Skin Ageing (Nutrients)
  2. 02Park et al. 2010 — Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans (Nutrition & Metabolism)
  3. 03Examine.com — Astaxanthin

Last reviewed2026-05-24